LLY

993.94

+2.07%↑

JNJ

227.13

+2.87%↑

ABBV

210.66

+3.75%↑

UNH

392.07

+3.44%↑

AZN

185.54

+1.61%↑

LLY

993.94

+2.07%↑

JNJ

227.13

+2.87%↑

ABBV

210.66

+3.75%↑

UNH

392.07

+3.44%↑

AZN

185.54

+1.61%↑

LLY

993.94

+2.07%↑

JNJ

227.13

+2.87%↑

ABBV

210.66

+3.75%↑

UNH

392.07

+3.44%↑

AZN

185.54

+1.61%↑

LLY

993.94

+2.07%↑

JNJ

227.13

+2.87%↑

ABBV

210.66

+3.75%↑

UNH

392.07

+3.44%↑

AZN

185.54

+1.61%↑

LLY

993.94

+2.07%↑

JNJ

227.13

+2.87%↑

ABBV

210.66

+3.75%↑

UNH

392.07

+3.44%↑

AZN

185.54

+1.61%↑

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Open

SectorHealthcare

65.72 -2.14

Buy Sell

Overview

Share price change

24h

Current

Min

66.23

Max

67.97

Key metrics
By Trading Economics
Income	35M 50M
Sales	32M 108M
Profit margin	45.833
Employees	104
EBITDA	29M 68M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+15.24% upside

Dividends
By Dow Jones
Next Earnings	15 maj 2026

Market Stats
By TradingEconomics
Market Cap	495M 2B
Previous open	67.86
Previous close	65.72

News Sentiment

By Acuity

23%

77%

70 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

19.25 / 21.135 Support & Resistance

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 maj 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 maj 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 maj 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 maj 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 maj 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 maj 2026, 22:32 UTC

Earnings

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 maj 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 maj 2026, 21:49 UTC

Earnings

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 maj 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 maj 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 maj 2026, 21:23 UTC

Acquisitions, Mergers, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 maj 2026, 21:12 UTC

Earnings

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 maj 2026, 21:12 UTC

Earnings

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 maj 2026, 20:44 UTC

Earnings

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 maj 2026, 20:43 UTC

Earnings

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 maj 2026, 20:32 UTC

Earnings

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 maj 2026, 20:32 UTC

Earnings

CleanSpark 2Q Rev $136.4M >CLSK

11 maj 2026, 20:30 UTC

Earnings

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Cont Ops EPS $2.24 >STE

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Rev $1.6B >STE

11 maj 2026, 20:30 UTC

Earnings

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Adj EPS $2.83 >STE

11 maj 2026, 20:22 UTC

Hot Stocks

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 maj 2026, 19:37 UTC

Earnings

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 maj 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

15.24% upside

12 Months Forecast

Average 78.27 USD 15.24%

High 140 USD

Low 50 USD

Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

70 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.